Supriya Lifescience Ltd details tax provisions for FY26 dividend
Supriya Lifescience Ltd has outlined the tax deduction requirements for the final dividend of Re 1.00 per share for FY25-26. Resident shareholders face a 10% TDS, exempt if dividends are under Rs 10,000, while non-residents face 20% withholding tax. Shareholders must submit necessary documentation to the Registrar & Share Transfer Agent by July 15, 2026, to ensure appropriate tax deduction.
*this image is generated using AI for illustrative purposes only.
Supriya Lifescience Ltd has detailed the tax deduction provisions for the final dividend of Re 1.00 per share recommended for the financial year 2025-26. The Board of Directors approved the recommendation at its meeting held on May 27, 2026. The dividend payout, representing 50% of the face value of Rs 2 per equity share, is taxable in the hands of shareholders under the Income Tax Act, 2025. The company will deduct tax at source (TDS) at the time of payment, with rates varying based on the residential status and category of the shareholder.
Tax Deduction for Resident Shareholders
For resident shareholders, TDS will be deducted at 10% on the dividend amount under Section 393(1) and Section 393(4) of the Act. However, no TDS will apply to resident individuals if the aggregate dividend paid during the tax year 2026-27 does not exceed Rs 10,000. Shareholders with valid Permanent Account Numbers (PAN) linked to Aadhaar will be subject to the standard rate, while those with inoperative PAN or missing PAN will face higher tax rates. Exemptions are available for specific entities such as insurance companies, mutual funds, and Alternative Investment Funds (AIF) upon submission of valid self-declaration forms.
Provisions for Non-Resident Shareholders
Non-resident shareholders, including Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs), are subject to a withholding tax of 20% plus applicable surcharge and cess. These shareholders may opt for benefits under the Double Taxation Avoidance Agreement (DTAA) if more favorable. To avail DTAA benefits, non-resident shareholders must submit a self-attested copy of their PAN, a valid Tax Residency Certificate (TRC) for TY 2026-27, and E-Form 41 filed on the income tax portal. The company reserves the right to apply DTAA rates at its sole discretion following a satisfactory review of the submitted documents.
Compliance and Documentation Requirements
Shareholders must ensure their details, including PAN, residential status, and bank account information, are updated with their depository participants or the company's Registrar & Share Transfer Agent, MUFG Intime India Private Limited. Documents claiming exemption or lower tax rates must be submitted to the RTA on or before July 15, 2026. The company will not accept any communication regarding tax determination after this date. Shareholders are advised that any excess tax deducted due to missing or defective documentation can be claimed as a refund by filing an income tax return.
| Shareholder Category | TDS Rate | Key Conditions |
|---|---|---|
| Resident Individuals | 10% | Exempt if total dividend ≤ Rs 10,000; valid PAN required. |
| Resident Non-Individuals | 10% | Exemptions available for Insurance, Mutual Funds, AIF with declarations. |
| Non-Residents | 20% + surcharge & cess | DTAA benefits optional with TRC and E-Form 41. |
Historical Stock Returns for Supriya Lifescience
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.32% | -14.11% | -11.25% | +16.00% | +20.50% | +118.65% |
How will the new tax deduction provisions impact shareholder yield expectations for the financial year 2025-26?
What steps should non-resident shareholders take to ensure timely submission of DTAA documentation before the July 15, 2026 deadline?
Could the stricter compliance requirements for PAN and Aadhaar linkage lead to a reduction in retail investor participation?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
